Acute pancreatitis

There are 107 papers on acute pancreatitis in aging research: 1 trial and 50 observational studies in people, 11 in animals, 38 reviews. The newest story, Nov 10, 2026: “Artery disease exceeded pancreas inflammation at most blood fat levels”.

Disease

107 papers study it33 more mention it53 findings

15 new papers in 30 daysSee all 140 papers on acute pancreatitis

At a glance

Acute pancreatitis is linked with shorter lifespan and higher mortality in human cohorts, while accelerated PhenoAge is linked with higher pancreatitis risk. In mice, microbiota from older rather than younger human donors worsen pancreatitis. Human cohorts report lower risk or no clear link with GLP-1 receptor agonists; a preprint reports no clear effect in placebo-controlled trials.

53 findings in 40 papers from 2021 to 2026, 13 of them since April 2026

“The temporal association, exclusion of alternative causes, and improvement following drug withdrawal (positive dechallenge), together with a Naranjo Adverse Drug Reaction Probability Scale score of 7, support a probable drug-related association”
Probable Vildagliptin-Associated Acute Pancreatitis in a Patient With Well-Controlled Type 2 Diabetes Mellitus: A Case ReportCureus2026doi:10.7759/cureus.111849
  • Human trial1
  • Humans50
  • Animals11
  • In silico1

Interventions

13

GLP-1 receptor agonists

no changein humans7OR 0.99–1.24

7 studies
  1. GLP-1 receptor agonists showed no clear effect on acute pancreatitis in humans (versus placebo in placebo-controlled randomized trials) (OR 0.99 (95% CI 0.67 to 1.45)).

    Human trialversus placebo in placebo-controlled randomized trialsn = 40,274

  2. GLP-1 receptor agonists were not clearly linked with acute pancreatitis in humans (Compared with empagliflozin or dapagliflozin).

    HumansCompared with empagliflozin or dapagliflozin

  3. GLP-1 receptor agonists were not clearly linked with acute pancreatitis in humans (post-operative use after bariatric surgery vs no GLP-1 use).

    Humanspost-operative use after bariatric surgery vs no GLP-1 use12 monthsn = 18,017

  4. GLP-1 receptor agonists were not clearly linked with acute pancreatitis in humans.

    Humanscompared with dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter 2 inhibitors

  5. GLP-1 receptor agonists showed no clear effect on acute pancreatitis in humans (Meta-analyses of randomized controlled trials) (MH-OR 1.24 [0.94, 1.64]; P = .13).

    ReviewMeta-analyses of randomized controlled trials

  6. GLP-1 receptor agonists showed no clear effect on acute pancreatitis in humans.

    Review

  7. GLP-1 receptor agonists showed no clear effect on acute pancreatitis in adults at high cardiovascular risk.

    Reviewin adults at high cardiovascular risk

More on GLP-1 receptor agonists

Tirzepatide

no changein humans1upin humans1RR 0.78

2 studies
  1. Tirzepatide showed no clear effect on acute pancreatitis in humans (pooled RCTs; 10 mg vs 5 mg comparison) (RR 0.78, 95% CI 0.29-2.09).

    Human trialpooled RCTs; 10 mg vs 5 mg comparison10 mg vs 5 mg once weeklyn = 15,471

  2. Tirzepatide is linked with acute pancreatitis in humans (two days after switching from semaglutide) (serum lipase 847 U/L).

    Humanstwo days after switching from semaglutidemalesn = 1

More on Tirzepatide

SGLT2 inhibitors

no changein humans1

1 study
  1. SGLT2 inhibitors were not clearly linked with acute pancreatitis in humans (falsification outcome, 1 and 5 years after TAVR).

    Humansfalsification outcome, 1 and 5 years after TAVR5 yearsn = 2,020

More on SGLT2 inhibitors

Manganese

downin humans1

1 study
  1. Manganese is linked with less acute pancreatitis in humans (U-shaped dose-response).

    HumansU-shaped dose-responseserum level

More on Manganese

Magnesium

downin humans1

1 study
  1. Magnesium is linked with less acute pancreatitis in humans.

    Humansserum level

More on Magnesium

Copper

downin humans1

1 study
  1. Copper is linked with less acute pancreatitis in humans.

    Humansserum level

More on Copper

Orforglipron

no changein humans1

1 study
  1. Orforglipron showed no clear effect on acute pancreatitis in humans (no significant difference).

    Reviewn = 6,140

More on Orforglipron

DPP-4 inhibitors

no changein humans1HR 0.97

1 study
  1. DPP-4 inhibitors were not clearly linked with acute pancreatitis in humans (medication-naïve individuals with diabetes) (adjusted HR 0.97, 95% CI 0.51-1.83).

    Humansmedication-naïve individuals with diabetes

More on DPP-4 inhibitors

Semaglutide

upin humans1

1 study
  1. Semaglutide is linked with acute pancreatitis in humans (single case report; Naranjo score 4 (probable cause)) (Naranjo score of 4 (probable cause)).

    Humanssingle case report; Naranjo score 4 (probable cause)once-weekly subcutaneouspancreas2 mgsix monthsmalesn = 1

More on Semaglutide

Antibiotics

downin mice1

1 study
  1. Antibiotics protect against acute pancreatitis in mice (before acute pancreatitis induction in mice with aged gut microbiota).

    Animalsbefore acute pancreatitis induction in mice with aged gut microbiota

More on Antibiotics

All 13

Effects

4

Lifespan

downin humans1

1 study
  1. Acute pancreatitis is linked with shorter lifespan in humans (69 years vs 81 years, p < 0.001).

    Humans

Serum amylase

upin rats1

1 study
  1. Acute pancreatitis increases serum amylase in L-arginine-induced acute pancreatitis model.

    Animalsin L-arginine-induced acute pancreatitis model

More on Serum amylase

SIRT1

downin rats1

1 study
  1. Acute pancreatitis decreases SIRT1 in L-arginine-induced acute pancreatitis model.

    Animalsin L-arginine-induced acute pancreatitis model

More on SIRT1

NAD+

downin mice1

1 study
  1. Acute pancreatitis decreases NAD+ in mice.

    Animalspancreas

More on NAD+

Associations

19

GLP-1 receptor agonists

downin humans4upin humans3HR 0.247–1.34

7 studies
  1. GLP-1 receptor agonists are associated with acute pancreatitis in humans (Adults with type 2 diabetes).

    HumansAdults with type 2 diabetes~56.4% males

  2. GLP-1 receptor agonists are linked with a lower risk of acute pancreatitis in humans (Obesity and type 2 diabetes; compared with DPP-4 inhibitors) (HR 0.68, 95% CI 0.61–0.76).

    HumansObesity and type 2 diabetes; compared with DPP-4 inhibitors1 yearn = 281,283

  3. GLP-1 receptor agonists are linked with a lower risk of acute pancreatitis in humans (HR 0.247, 95% CI 0.149-0.409; 2.4% vs 10.8%).

    Humansnon-diabetic adults with chronic pancreatitis; propensity-matched retrospective TriNetX cohort1 to 1095 days after index daten = 1,422

  4. GLP-1 receptor agonists are linked with a lower risk of acute pancreatitis in patients with diabetes and chronic pancreatitis vs SGLT2 inhibitors (HR 0.586, 95% CI 0.437–0.786).

    Humansin patients with diabetes and chronic pancreatitis vs SGLT2 inhibitorspancreasday 1 through day 1825n = 3,373

  5. GLP-1 receptor agonists are linked with a lower risk of acute pancreatitis in humans (compared with lipid-lowering agents in hypertriglyceridemia) (1.2% vs 5.6%; RR 0.208).

    Humanscompared with lipid-lowering agents in hypertriglyceridemian = 296,961

  6. GLP-1 receptor agonists are associated with acute pancreatitis in humans (Real-world data) (HR 1.340; 95% CI, 1.239-1.449; P = .019).

    ReviewReal-world datafirst 6 months of treatment

  7. GLP-1 receptor agonists raise the risk of acute pancreatitis in T2DM patients.

    Reviewin T2DM patients

More on GLP-1 receptor agonists

Type 2 diabetes

upin humans1upin silico1

2 studies
  1. Acute pancreatitis is linked with a higher risk of type 2 diabetes in humans.

    Humans13.7 years

  2. Acute pancreatitis predicts type 2 diabetes in silico (using logistic regression machine learning model trained on EHR data) (AUROC 0.79).

    In silicousing logistic regression machine learning model trained on EHR datan = 58,746

More on Type 2 diabetes

Mortality

upin humans2

2 studies
  1. Acute pancreatitis is linked with a higher risk of mortality in humans.

    Humans13.7 years

  2. Acute pancreatitis is linked with a higher risk of mortality in humans (aHR 1.61, 95% CI 1.58-1.65, p < 0.001).

    Humans

Tirzepatide

upin humans1upin reviews1

2 studies
  1. Tirzepatide raises the risk of acute pancreatitis in humans (unsupervised off-label use / self-medication).

    Reviewunsupervised off-label use / self-medication

  2. Tirzepatide is associated with acute pancreatitis.

    Review

More on Tirzepatide

SGLT2 inhibitors

upin humans1downin humans1HR 0.82

2 studies
  1. SGLT2 inhibitors are associated with acute pancreatitis in humans (Hospitalized Chinese patients with chronic kidney disease; comparison with nonusers).

    HumansHospitalized Chinese patients with chronic kidney disease; comparison with nonusers

  2. SGLT2 inhibitors are linked with a lower risk of acute pancreatitis in humans (compared with dipeptidyl peptidase-4 inhibitors) (HR 0.82; 95% CI 0.68-0.98).

    Humanscompared with dipeptidyl peptidase-4 inhibitors

More on SGLT2 inhibitors

Metformin

downin humans1RR 1.57

1 study
  1. Metformin is associated with acute pancreatitis in humans (0.36% vs 0.56%; reported RR 1.57 (non-users vs users), 95% CI 1.35–1.83).

    HumansType 2 diabetes mellitus without prior pancreatitis; compared with patients not on medication≥12 months of exposuren = 74,930

More on Metformin

PhenoAgeAccel

upin humans1HR 1.637

1 study
  1. PhenoAgeAccel is linked with a higher risk of acute pancreatitis in humans (fully adjusted Cox model, compared with G1) (HR 1.637, 95% CI 1.352-1.981).

    Humansfully adjusted Cox model, compared with G1

More on PhenoAgeAccel

Vildagliptin

upin humans1

1 study
  1. Vildagliptin is associated with acute pancreatitis in a patient with well-controlled type 2 diabetes mellitus (Naranjo score 7).

    Human trialin a patient with well-controlled type 2 diabetes mellituspancreassix monthsmales

More on Vildagliptin

Plozasiran

downin humans1

1 study
  1. Plozasiran lowers the risk of acute pancreatitis in familial chylomicronemia syndrome patients (PALISADE trial).

    Reviewin familial chylomicronemia syndrome patients (PALISADE trial)

More on Plozasiran

Familial chylomicronemia syndrome

upin humans1

1 study
  1. Familial chylomicronemia syndrome raises the risk of acute pancreatitis in humans (plasma triglycerides >10 mmol/L) (plasma triglycerides >10 mmol/L; high risk).

    Reviewplasma triglycerides >10 mmol/L

More on Familial chylomicronemia syndrome

All 19

Trial sponsors

Funding

3 grants since 2018

National Institute on Aging$1.3MNational Institute of Diabetes and Digestive and Kidney Diseases$655K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human studies link acute pancreatitis to higher mortality and type 2 diabetes risk, and PhenoAgeAccel to higher acute pancreatitis risk. GLP-1 receptor agonists are associated with lower acute pancreatitis risk in non-diabetic adults with chronic pancreatitis. An in silico EHR-based logistic regression model predicts type 2 diabetes using acute pancreatitis, with AUROC 0.79.

  2. Summary written from the findings.

Latest

Dec 2025: 4Jan 2026: 7Feb 2026: 8Mar 2026: 9Apr 2026: 2May 2026: 0Jun 2026: 3Jul 2026: 4Aug 2026: 4Sep 2026: 5Oct 2026: 8Nov 2026: 1064 papers in 12 months
Atherosclerosis

Artery disease exceeded pancreas inflammation at most blood fat levels

Across four Danish and UK cohorts, artery disease occurred more often than acute pancreas inflammation at blood triglycerides up to 30 millimoles per liter.Across four Danish and UK cohorts, artery disease occurred more often than acute pancreas inflammation at blood triglycerides up to 30 millimoles per liter.

Cohort studyPopulations

See all 140 papers on acute pancreatitis